Transcript:
My name is Justin Balko. I am a translational researcher at Vanderbilt University Medical Center representing Vanderbilt Ingram Cancer Center in Nashville, Tennessee, United States of America. The title of our state-of-the-art session to be presented at the 2024 San Antonio Breast Cancer Symposium is “The Winding Road of Immune Biomarkers and Early Breast Cancer.” There’ll be three of us speaking Dr. Priyanka Sharma from Kansas University Medical Center, myself and Roberto Salgado, who is a clinical pathologist, heavily involved in biomarkers. So the three presentations to be given are going to cover the types of immune biomarkers that are either being tested translationally in clinical studies, as well as those that are being actively deployed to some degree in clinical practice, as well as large phase three clinical trials across the world. Dr. Roberto Salgado is going to describe his journey in uncovering and understanding the role of tumor infiltrating lymphocytes, something that’s been a very near and dear area of research to his heart, which is essentially the scoring of lymphocytes in the immune microenvironment in breast cancers, and has largely been shown by Dr. Salgado and others to be first a prognostic biomarker and then also have some predictive capabilities on patient response to chemotherapy, and in some cases chemotherapy plus immunotherapy.
